As Src is essential for the endosomal delivery of the FGFR4 signaling complex, we hypothesized that an Src inhibitor may inhibit the proliferation of the HCC cell lines in which the FGF19–FGFR4 axis is active. Here, FGF19 is linked to hepatocellular carcinoma.